Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
US2020208133A1
Modified urokinase-type plasminogen activator polypeptides and methods of use
WO2020140101A1
Modified urokinase-type plasminogen activator polypeptides and methods of use
WO2018237201A1
Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
AU2015224596A1
Factor vii polypeptides that are modified and uses thereof
AU2013204377A1
Modified factor vii polypeptides and uses thereof
AU2013204511A1
Modified factor ix polypeptides and uses thereof
AU2013203608A1
Factor vii polypeptides that are modified and uses thereof
AU2013202890A1
Protease screening methods and proteases identified thereby
MX2015001083A
Modified factor x polypeptides and uses thereof.
TW201242975A
Modified factor ix polypeptides and uses thereof
AU2011218753A1
Modified proteases that inhibit complement activation
IL203377A
Methods of manufacturing stereoisomerically enriched (2s,3r)- n -(2-((3 - pyridinyl) methyl)-1-azabicyclo [2.2.2]oct -3 -yl) benzofuran-2-carboxamide and intermediates for use in the methods
TW201431877A
Factor vii polypeptides that are modified and uses thereof
NZ593611A
Modified factor vii polypeptides and uses thereof
CA2791144A1
Protease screening methods and proteases identified thereby
AU2007307260A1
Protease screening methods and proteases identified thereby
EP2423305A1
Modified coagulation factor IX polypeptides and use thereof for treatment
WO2005123119A2
Administration of neutral endopeptidase to treat inflammatory bowel disease
US2006002916A1
Mutant MT-SP1 proteases with altered substrate specificity or activity
